These differentiated cells can contribute to drug development for Down syndrome in two ways: (1) Correction of gene expression levels, i.e., ets2, dyrk1a, dscr1, and app; (2) Increased frequency of trisomic rescue. This evidence concerns the gene ETS2 and Down syndrome.